KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Invested Capital: 2009-2025

Historic Invested Capital for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $2.0 billion.

  • Halozyme Therapeutics' Invested Capital rose 2.95% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 2.95%. This contributed to the annual value of $1.9 billion for FY2024, which is 18.10% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Invested Capital stood at $2.0 billion, which was up 9.38% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Invested Capital registered a high of $2.0 billion during Q3 2025, and its lowest value of $852.3 million during Q1 2021.
  • Moreover, its 3-year median value for Invested Capital was $1.8 billion (2024), whereas its average is $1.8 billion.
  • In the last 5 years, Halozyme Therapeutics' Invested Capital spiked by 116.83% in 2021 and then declined by 5.54% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Invested Capital (Quarterly) stood at $984.2 million in 2021, then soared by 70.28% to $1.7 billion in 2022, then dropped by 5.54% to $1.6 billion in 2023, then grew by 18.10% to $1.9 billion in 2024, then increased by 2.95% to $2.0 billion in 2025.
  • Its Invested Capital stands at $2.0 billion for Q3 2025, versus $1.8 billion for Q2 2025 and $2.0 billion for Q1 2025.